Efficacy and Safety of CK3773274 in Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Summary

This study focuses on individuals who have obstructive hypertrophic cardiomyopathy (oHCM, a condition in which the heart muscle is abnormally thick) and who also have left ventricular outflow tract (LVOT) obstruction, a condition that interferes with the flow of blood from the heart to the body. The purpose of the study is to compare the effects of an experimental drug called CK-3773274 and placebo (inactive substance) on the exercise abilities and health status of patients with oHCM. The safety and tolerability of CK-3773274 will also be studied. CK-3773274 may reduce symptoms of oHCM by reducing LVOT obstruction. Researchers will measure the amount of CK-3773274 in the blood at various times, as well the effect of the drug on the patient’s oHCM. Throughout the study, participants will continue with their regular (standard-of-care) medications for oHCM. They will be randomly assigned to receive either CK-3773274 or placebo.


Inclusion Criteria

  • Males and females between 18 and 85 years of age, inclusive, at screening.
  • Body mass index <35 kg/m2.
  • Diagnosed with HCM per the following criteria:
Show more

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION

Details
Disease Type/Condition

Cardiomyopathy

Principal Investigator

Rader, Florian

Age Group

Adult

Phase

III

IRB Number

STUDY00001817

ClinicalTrials.gov ID

NCT05186818

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Cardiomyopathy

Principal Investigator

Rader, Florian

Age Group

Adult

Phase

III

IRB Number

CY6031

ClinicalTrials.gov ID

NCT05186818

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?